Pharmaceutical distributor Morris & Dickson, headquartered in Shreveport, LA, signed a non-binding Letter of Intent (LOI) to acquire Prodigy Health — a privately held, national specialty distributor of plasma derivatives, specialty drugs and vaccines.

In a Dec. 8 news release, the company said the proposed acquisition of Austin, TX-based Prodigy Health underscores Morris & Dickson’s accelerated growth in serving both inpatient and outpatient care settings for health systems, hospitals and provider-owned community clinics and infusion centers.

With the acquisition, M&D will expand its product portfolio to include a comprehensive on-shelf inventory of plasma derivatives, coagulation products, immune globulin, recombinants and vaccines for both acute and non-acute care. All will be available through one company and one ordering portal, supported by M&D’s distribution services and account support team.

Prodigy Health customers will also gain access to 30,000 SKUs of full-line and specialty products through the M&D portfolio, plus the strength of an independent organization with 180-plus years of serving pharmacies.

“Signing the LOI with Prodigy Health is another important step in our growth strategy as we continue to expand nationally in support of pharmacies across all sites of care,” Morris & Dickson CEO Jody Hatcher said. “The Prodigy team has built extensive capabilities in the management of these high-cost drugs for bleeding disorders and immune deficiencies, and they are aligned to our goal of creating an alternative, more agile and responsive distribution solution for pharmacies. This acquisition underscores our ability to serve customers in a more meaningful way with our full focus on their pharmacy success.”

Transaction terms were not disclosed and deal close is anticipated in Q1 2026. Both organizations will operate independently upon completion.